Donald J. Osterling

Discovery of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor 2-[(<i>R</i>)-2-methylpyrrolidin-2-yl]-1<i>H</i>-benzimidazole-4-carboxamide (ABT-888) for the Treatment of Cancer

Thomas D. Penning, Gui‐Dong Zhu, Viraj B. Gandhi et al. · Journal of Medicinal Chemistry · 2008 · 269 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +14

Mechanistic Dissection of PARP1 Trapping and the Impact on <i>In Vivo</i> Tolerability and Efficacy of PARP Inhibitors

Todd A. Hopkins, Yan Shi, Luis E. Rodrı́guez et al. · Molecular Cancer Research · 2015 · 267 citations

Medicine, Oncology, Pharmacology +17

The EED protein–protein interaction inhibitor A-395 inactivates the PRC2 complex

Yupeng He, Sujatha Selvaraju, Michael L. Curtin et al. · Nature Chemical Biology · 2017 · 233 citations · Full text

Life Sciences, Cell Biology, Molecular Biology +9

Discovery of<i>N</i>-(4-(3-Amino-1<i>H</i>-indazol-4-yl)phenyl)-<i>N</i>‘-(2-fluoro-5-methylphenyl)urea (ABT-869), a 3-Aminoindazole-Based Orally Active Multitargeted Receptor Tyrosine Kinase Inhibitor

Yujia Dai, Kresna Hartandi, Zhiqin Ji et al. · Journal of Medicinal Chemistry · 2007 · 185 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +14

Relationship between amorphous solid dispersion in vivo absorption and in vitro dissolution: phase behavior during dissolution, speciation, and membrane mass transport

Venecia R. Wilson, Xiaochun Lou, Donald J. Osterling et al. · Journal of Controlled Release · 2018 · 161 citations

Pharmacy, Pharmaceutics, Pharmacokinetics +17